1. Taiwan Stocks

  2. •

    Electronic technology

  3. •

    Electronic equipment/Instruments
Taiwan Biomaterial Co., Ltd.

Taiwan Biomaterial Co., Ltd.

TTPEX:6649
37.20
TWD
-0.05
(-0.13%)
0.79EPS
48.16P/E
1.60BMarket Cap
Taiwan Biomaterial Co., Ltd.
TPEX:6649
(Taipei Exchange)

Recent

price

37.20

P/E

ratio

48.16

div

yld

2.69%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
- -
- -
0.07
0.08
0.07
0.03
0.5
0.55
1.26
3.12
1.73
2.3
5.25
4.34
Revenue per Share
- -
-5.58
-4.77
-1.59
-1.87
-1.95
-2.17
-1.68
-1.44
0.83
-0.24
-0.04
1.4
0.79
Basic EPS, GAAP
- -
-0.01
-5.18
-1.86
-1.65
-2.1
-4.72
-5.89
-1.7
-0.2
-0.32
0.33
1.09
-1.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.2
- -
- -
1
Dividend per Share
1.72
3.24
4.66
8
16.79
14.9
15.36
13.74
12.81
15.39
14.95
14.91
16.31
15.33
Book Value per Share
1.67
3.16
4.06
7.47
16.5
14.69
15.22
13.68
12.76
15.33
14.91
14.88
16.27
15.29
Tangible Book Value per Share
17
5
10
20
27
31
33
33
33
41
42
42
42
42
Basic Weighted Avg Shares
- -
- -
1
2
2
1
17
18
42
127
73
97
220
182
Sales/Revenue/Turnover
- -
- -
-7,527.17
-2,330.72
-2,820.76
-6,764.14
-441.59
-360.22
-136.1
20
-19.53
-11.63
27.6
10.12
Operating Margin (%)
- -
- -
2
5
6
6
11
12
11
17
18
18
17
16
Depreciation Expense
- -
-26
-50
-33
-50
-61
-71
-55
-47
34
-10
-2
59
33
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-7,322.32
-2,077.82
-2,641.25
-6,029.98
-430.99
-306.31
-113.84
26.51
-13.91
-1.79
26.74
18.19
Profit Margin (%)
25
45
58
135
488
430
368
210
113
347
339
345
414
363
Working Capital
- -
- -
- -
- -
- -
- -
71
74
67
61
56
53
48
47
LT Debt
28
54
77
165
521
462
524
469
423
646
628
626
685
644
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.18
- -
- -
8.56
2.63
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.7
- -
- -
8.4
4.83
Return on Capital (%)
- -
-64.3
-76.23
-26.88
-14.46
-12.32
-14.45
-11.15
-10.64
6.31
-1.59
-0.28
8.99
5.12
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4
4
5
LT Borrowings
- -
- -
- -
LT Finance Leases
48
47
47
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
42
Market Capitalization
1,953
1,869
1,596

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
469
444
401
Cash, Cash Equivalents & STI
356
306
247
Accounts Receivable, Net
24
22
16
Inventories
59
72
89
Total Current Liabilities
55
81
38
Payables & Accruals
- -
- -
- -
ST Debt
4
4
5
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.02%
9.86%
9.41%
Free Cash Flow
13.29%
-12.98%
231.06%
Net Income, GAAP
-386.55%
-780.11%
-3,502.19%
Sales/Revenue/Turnover
211.46%
90.81%
128.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19
21
27
29
97
2025
68
34
73
46
220
2026
26
37
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.03
-0.03
0.04
-0.04
2025
0.79
-0.16
0.68
0.09
1.4
2026
- -
0.01
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
1
- -
- -
- -
- -
Similar Companies
Advantest Corp. (TSE:6857)
Unusual Machines, Inc. (AMEX:UMAC)
FuelCell Energy, Inc. (NASDAQ:FCEL)
Lasertec Corp. (TSE:6920)
Hitachi Energy India Limited (NSE:POWERINDIA)
Keysight Technologies Inc. (NYSE:KEYS)
Business
Taiwan Biomaterial Co., Ltd. specializes in the research, development, manufacture, and sale of high-end implantable medical devices and biomedical materials in Taiwan. Its core product portfolio includes Foamagen, a foamy dura substitute used in neurosurgery; stroke thrombus negative pressure removal catheter systems designed for suction and removal of cerebrovascular embolism blood clots; nickel-titanium guidewires for guiding cerebral vascular surgeries; as well as tissue repair and regeneration products aimed at treating early osteoarthritis. The company integrates advanced biomedical technologies with clinical insights to develop innovative surgical materials and interventional devices. Founded in 2010, Taiwan Biomaterial is headquartered in Zhubei City, Hsinchu County, Taiwan. In recent years, Taiwan Biomaterial has experienced significant growth, with a reported sales increase of over 32% in 2024 and a strong profitability turnaround in 2025. The company posted notable earnings growth with third quarter 2025 sales rising to TWD 72.78 million from TWD 27.49 million the previous year and net income reversing from a loss to a TWD 28.65 million profit. This financial improvement is underpinned by expanding adoption of its medical device offerings and ongoing research and development initiatives. Taiwan Biomaterial continues to collaborate closely with clinicians to identify unmet surgical needs and translate these into commercially viable products, enhancing its local market position. The company operates primarily within the medical equipment and healthcare supplies industry sectors, focusing on the Taiwanese market where it provides specialized medical devices for neurosurgery, stroke intervention, and orthopedic tissue repair. Its product development philosophy emphasizes a combination of translational research, clinical cooperation, and technological integration, supported by modern manufacturing capabilities sourced both domestically and internationally. Taiwan Biomaterial maintains a commitment to innovation and quality in implantable medical devices, positioning itself as a key player in Taiwan’s healthcare and medical device landscape. There have been no recent publicly disclosed transformative partnerships, acquisitions, or name changes reported in the last two years. The company’s stable growth trajectory and enhanced financial performance reflect its strategic focus on expanding product lines and market penetration in the specialized medical device sector.